Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOENIX-CCA3: Futibatinib vs Gemcitabine-Cisplatin in iCCA
NCT04093362Phase 3Terminated
- Sponsor
- Taiho Oncology
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of futibatinib in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Taiho Oncology. Primary endpoint: Progression-Free Survival at 28 months. Started Jan 2021; status: terminated.
02
Drugs
futibatinib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04093362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04093362.